PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2010 | 3 | 94-114
Article title

RNA interference-based therapeutics in anticancer therapy

Title variants
Languages of publication
EN
Abstracts
EN
RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing and its discovery led to wide applications. Short interfering RNA (siRNA), which induces RNAi, has been experimentally introduced as a cancer therapy and is expected to be developed as a nucleic acid-based medicine. Potential success of siRNA cancer therapies depends on selection of appropriate gene targets and candidate targets include genes associated with cell proliferation, metastasis, angiogenesis, and drug resistance. In vivo systemic delivery of siRNA-based therapeutics to tumour tissues is challenging and the major limitations of siRNA therapeutic use are its degradation by serum nucleases, poor cellular uptake and rapid renal clearance following systemic administration. Several siRNA-based therapeutics are already in clinical trials. Further development of anti-cancer therapeutic siRNAs depends on development of nanocarriers, nuclease-resistant chemically modified siRNAs and variety of synthetic or natural lipids and polymers to systemically deliver siRNA. Here, we review potential approaches for delivery of RNAi based therapeutic in cancer therapy, results of current studies and clinical trials which demonstrate that the use of targeted siRNA offers promising strategies for cancer therapies.
Keywords
Publisher

Journal
Year
Issue
3
Pages
94-114
Physical description
Contributors
author
author
author
References
Document Type
REVIEW
Publication order reference
Bozena Kaminska, Pracownia Regulacji Transkrypcji, Instytut Biologii Doswiadczalnej PAN im. M. Nenckiego, ul. Pasteura 3, Warszawa, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-bb4d5428-7799-3add-ba55-18f378adc295
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.